Skip to content

Commit

Permalink
document + update
Browse files Browse the repository at this point in the history
  • Loading branch information
benoit committed Nov 2, 2022
1 parent 0826793 commit ef396be
Show file tree
Hide file tree
Showing 2 changed files with 14 additions and 30 deletions.
16 changes: 0 additions & 16 deletions man/aet01_1.Rd
View file

Some generated files are not rendered by default. Learn more about how customized files appear on GitHub.

28 changes: 14 additions & 14 deletions tests/testthat/_snaps/aet01.md
View file
Original file line number Diff line number Diff line change
Expand Up @@ -8,19 +8,19 @@
———————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 122 (91.0%) 123 (91.8%) 120 (90.9%)
Total number of AEs 609 622 703
Total number of deaths 22 (16.4%) 26 (19.4%) 19 (14.4%)
Total number of patients withdrawn from study due to an AE 6 (4.5%) 1 (0.7%) 2 (1.5%)
Total number of deaths 25 (18.7%) 23 (17.2%) 22 (16.7%)
Total number of patients withdrawn from study due to an AE 3 (2.2%) 6 (4.5%) 5 (3.8%)
Total number of patients with at least one
AE with fatal outcome 0 (0.0%) 0 (0.0%) 0 (0.0%)
Serious AE 0 (0.0%) 0 (0.0%) 0 (0.0%)
Serious AE leading to withdrawal from treatment 0 (0.0%) 0 (0.0%) 0 (0.0%)
Serious AE leading to dose modification/interruption 0 (0.0%) 0 (0.0%) 0 (0.0%)
Related Serious AE 0 (0.0%) 0 (0.0%) 0 (0.0%)
AE leading to withdrawal from treatment 23 (17.2%) 24 (17.9%) 27 (20.5%)
AE leading to dose modification/interruption 72 (53.7%) 65 (48.5%) 76 (57.6%)
AE leading to withdrawal from treatment 27 (20.1%) 26 (19.4%) 30 (22.7%)
AE leading to dose modification/interruption 66 (49.3%) 76 (56.7%) 74 (56.1%)
Related AE 105 (78.4%) 108 (80.6%) 109 (82.6%)
Related AE leading to withdrawal from treatment 6 (4.5%) 9 (6.7%) 13 (9.8%)
Related AE leading to dose modification/interruption 31 (23.1%) 31 (23.1%) 32 (24.2%)
Related AE leading to withdrawal from treatment 6 (4.5%) 12 (9.0%) 8 (6.1%)
Related AE leading to dose modification/interruption 29 (21.6%) 38 (28.4%) 38 (28.8%)
Severe AE (at greatest intensity) 91 (67.9%) 90 (67.2%) 93 (70.5%)

# aet01 can handle some NA values
Expand All @@ -33,18 +33,18 @@
———————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 122 (91.0%) 123 (91.8%) 120 (90.9%)
Total number of AEs 609 622 703
Total number of deaths 22 (16.4%) 26 (19.4%) 19 (14.4%)
Total number of patients withdrawn from study due to an AE 6 (4.5%) 1 (0.7%) 2 (1.5%)
Total number of deaths 25 (18.7%) 23 (17.2%) 22 (16.7%)
Total number of patients withdrawn from study due to an AE 3 (2.2%) 6 (4.5%) 5 (3.8%)
Total number of patients with at least one
AE with fatal outcome 76 (56.7%) 70 (52.2%) 75 (56.8%)
Serious AE 104 (77.6%) 101 (75.4%) 99 (75.0%)
Serious AE leading to withdrawal from treatment 8 (6.0%) 8 (6.0%) 7 (5.3%)
Serious AE leading to dose modification/interruption 36 (26.9%) 31 (23.1%) 26 (19.7%)
Serious AE leading to withdrawal from treatment 9 (6.7%) 6 (4.5%) 11 (8.3%)
Serious AE leading to dose modification/interruption 22 (16.4%) 26 (19.4%) 29 (22.0%)
Related Serious AE 76 (56.7%) 70 (52.2%) 75 (56.8%)
AE leading to withdrawal from treatment 23 (17.2%) 24 (17.9%) 27 (20.5%)
AE leading to dose modification/interruption 72 (53.7%) 65 (48.5%) 76 (57.6%)
AE leading to withdrawal from treatment 27 (20.1%) 26 (19.4%) 30 (22.7%)
AE leading to dose modification/interruption 66 (49.3%) 76 (56.7%) 74 (56.1%)
Related AE 105 (78.4%) 108 (80.6%) 109 (82.6%)
Related AE leading to withdrawal from treatment 6 (4.5%) 9 (6.7%) 13 (9.8%)
Related AE leading to dose modification/interruption 31 (23.1%) 31 (23.1%) 32 (24.2%)
Related AE leading to withdrawal from treatment 6 (4.5%) 12 (9.0%) 8 (6.1%)
Related AE leading to dose modification/interruption 29 (21.6%) 38 (28.4%) 38 (28.8%)
Severe AE (at greatest intensity) 91 (67.9%) 90 (67.2%) 93 (70.5%)

0 comments on commit ef396be

Please sign in to comment.